Intestinal Permeability and Intestinal Microbiota in Irritable Bowel Syndrome
Status:
Active, not recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
Patients with diarrhea-predominant irritable bowel syndrome (IBS) and functional dyspepsia
(FD) were examined and received treatment in the study. Severity of complaints and quality of
life patients were assessed according to questionnaires. The state of the intestinal barrier
(analysis of the protein composition, intestinal mucin levels in biopsies, serum zonulin
level in blood), the composition of the gut microbiota (16S rRNA gene sequencing), bacterial
metabolic function (short-chain fatty acid levels in feces), and the presence of gut
inflammation (levels of lymphocytes and eosinophils in biopsies) were assessed in the
patients. Patients were divided into 3 treatment groups: trimebutin + placebo, rebamipide +
placebo, trimebutin + rebamipide. The above parameters were compared in patients before and
after treatment.
Phase:
Phase 4
Details
Lead Sponsor:
I.M. Sechenov First Moscow State Medical University